A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

BACKGROUND: CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the immunotherapy of B cell malignancies. In this study we present the generation of a novel humanized anti-CD19 monoclonal antibody (mAb),...

Descripción completa

Detalles Bibliográficos
Autores principales: Breton, Caroline S, Nahimana, Aimable, Aubry, Dominique, Macoin, Julie, Moretti, Pierre, Bertschinger, Martin, Hou, Samuel, Duchosal, Michel A, Back, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021825/
https://www.ncbi.nlm.nih.gov/pubmed/24731302
http://dx.doi.org/10.1186/1756-8722-7-33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021825/
https://www.ncbi.nlm.nih.gov/pubmed/24731302
http://dx.doi.org/10.1186/1756-8722-7-33

Ejemplares similares